Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01415908 · ClinicalTrials.gov registry record · Phase 3

INFUSE®Bone Graft in Transforaminal Lumbar Interbody Fusion for Degenerative Disease of Lumbosacral Spine

A Phase 3 study, sponsored by Medtronic Spinal and Biologics.

Terminated
Registry status
Phase 3
Development phase
15
Enrollment target

NCT01415908 is a Phase 3 study that was terminated before completion, run by Medtronic Spinal and Biologics. The registered enrollment target is 15 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01415908, a Phase 3 study, was terminated before completion, sponsored by Medtronic Spinal and Biologics.

TERMINATED
Registry status
Phase 3
Development phase
15 participants
Enrollment target

Study Summary

This investigation will provide safety and effectiveness information on the use of INFUSE® Bone Graft with the CAPSTONE® Spinal System and CD HORIZON® Spinal System with a Transforaminal Lumbar Interbody Fusion (TLIF) surgical approach at one or two adjacent levels from L2-S1 to treat subjects with advanced degenerative disease of the lumbosacral spine.

Interventions

  • DEVICE INFUSE Bone Graft
  • OTHER Iliac Crest Bone Graft

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2011-07
Est. Completion 2015-01
Phase Phase 3

Sponsor

Medtronic Spinal and Biologics

26 total trials

What the Registry Record Tells You About NCT01415908

The ClinicalTrials.gov registry entry for NCT01415908 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic Spinal and Biologics, which has 26 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which INFUSE Bone Graft is the first listed.

NCT01415908 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01415908 about?

NCT01415908 is a clinical study titled "INFUSE®Bone Graft in Transforaminal Lumbar Interbody Fusion for Degenerative Disease of Lumbosacral Spine". This investigation will provide safety and effectiveness information on the use of INFUSE® Bone Graft with the CAPSTONE® Spinal System and CD HORIZON® Spinal System with a Transforaminal Lumbar Interbody Fusion (TLIF) surgical approach at one or two adjacent levels from L2-S1 to treat subjects with ...

What is the current status of trial NCT01415908?

This trial is currently terminated. It is a Phase 3 study. The enrollment target is 15 participants. The study started on 2011-07. Estimated completion is 2015-01.

What interventions are being tested in trial NCT01415908?

The interventions under investigation include: INFUSE Bone Graft (DEVICE), Iliac Crest Bone Graft (OTHER).

Who is sponsoring clinical trial NCT01415908?

This trial is sponsored by Medtronic Spinal and Biologics, which has 26 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.